Skip to main content
. 2020 Jan 4;2020:8016791. doi: 10.1155/2020/8016791

Table 4.

Characteristics and bivariate analysis of study participants by BMI at their last clinic visit (BMI-2) at Princess Marina Hospital and Bontleng anti-retroviral therapy clinics in Botswana categorized as underweight, normal and overweight/obesity (N = 531).

Characteristics BMI after patients' initiation on ART (BMI-2)
Total Underweight Normal BMI ††Overweight/obesity UOR P-value
Age after ART initiation [years, mean ± SD] 47.6 ± 9.6 50.1 ± 14.1 47.6 ± 9.6 47.3 ± 8.5 0.180

ART regimen
Second/third-line, n (%) 208 (39.2) 13 (29.5) 101 (43.3) 88 (36.5) 1
First-line, n (%) 323 (60.8) 31 (70.5) 132 (56.7) 153 (63.5) 1.2 0.250
Duration of exposure to ART (months, mean ± SD) 84.9 ± 29.7 91.7 ± 28.0 87 ± 30.1 81 ± 29.3 0.190

Gender
Male, n (%) 163 (30.7) 28 (63.6) 89 (38.2) 45 (18.7) 1
Female, n (%) 368 (69.3) 16 (36.4) 144 (61.8) 196 (81.3) 3.0 0.001

CD4 cell count/mm3at last clinic visit
Median (IQR) 515 (310–691) 444 (270–597) 513 (375–686) 577 (416–732) 0.001

CD4 cell count/mm3categories at last clinic visit
≥350, n (%) 421 (79.3) 22 (50.0) 183 (78.5) 216 (89.6) 1
Nadir (0–200), n (%) 34 (6.4) 8 (18.2) 17 (7.3) 8 (3.3) 0.29 0.003
201–349, n (%) 76 (14.3) 14 (31.8) 33 (14.2) 17 (7.1) 0.27 0.001

DRC
Absent, n (%) 442 (83.2) 40 (90.9) 201 (86.3) 189 (78.4) 1
Present, n (%) 89 (16.8) 4 (9.1) 32 (13.7) 52 (21.6) 1.88 0.007

ART = antiretroviral therapy; BMI = body mass index; overweight/obesity = overweight or obesity and morbidly obese; UOR = unadjusted odds ratio; DRC = diabetes-related comorbidity; SD = standard deviation; p < 0.05; reference group; ††outcome of interest.